Participated · Series A · Aug 2020

GI Windows Medical is a clinical-stage medical device company focused on developing a fundamental breakthrough in anastomoses technology for both delivery and tissue fusion. The company holds patented technology and was spun out of Beacon Endoscopic (acquired by Covidien in 2014). Led by President and CEO Brian Tinkham, GI Windows is advancing its product through clinical-stage development. The company raised $16.4M in a Series A-1 financing to support further product development and clinical studies. Proceeds also included investments from existing shareholders and new investors such as the Kennedy Trust and the Coleman Trust. The company is based in West Bridgewater, Massachusetts. GI Windows Corp is a clinical-stage, venture-backed medical device company developing patented anastomoses and tissue-fusion technology for next-generation clinical procedures. The company aims to deliver what it calls the first fundamental breakthrough in anastomoses technology in the past 40 years to address unmet clinical needs and large market opportunities. Proceeds from financing will be used to support further product development and clinical studies. GI Windows reports significant strides in R&D and clinical procedural development over the past 12 months, according to CEO Brian Tinkham. The company was spun out of Beacon Endoscopic (acquired by Covidien in 2014) and is headquartered in West Bridgewater, MA.